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Summary
Background.— Currently, several anatomical approaches and intervention sites can be used to
perform transcatheter aortic valve implantations (TAVIs), often with no clinical indications for
choosing one or another. While these choices can have an impact on resource consumption, no
costing study is available in the European context to provide information on resource use and
assist decision-making.
Aims.— To provide comparative data on the cost of the TAVI procedure, depending on anatom-
ical approach and intervention site used, from a hospital perspective, and to analyze factors
associated with cost of hospital stay.
Methods.— Multicentre national registry data were collected in 16 centres between January
and October 2009. For 287 patients, a descriptive costing study and a multivariable analysis of
hospital stay cost were performed.
Results.— The mean cost of the TAVI procedure was D 22,876 and the mean initial hospital stay
cost was D 35,164. The procedure cost, excluding valve cost, did not differ between anatomical
approaches and was highest in the hybrid room and lowest in the catheterization laboratory.
Factors associated with higher hospital stay cost were transapical approach, Society of Thoracic
Surgeons score > 10%, warfarin use at inclusion, complications during procedure and pacemaker
implantation following valve implantation.
Conclusions.— If clinical considerations do not interfere, hospital staff may ﬁnd it economically
favorable to opt for the catheterization laboratory and against the hybrid room. The mean
hospital stay cost is higher than the tariff paid in 2011, a difference that has grown since the
change in tariff in 2012, representing an economic disincentive for the uptake of TAVI in France.
© 2013 Published by Elsevier Masson SAS.
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Résumé
Contexte.— Il n’existe souvent aucune indication clinique permettant de faire le choix entre
les différents types de salle et de voies d’abord disponibles pour effectuer une implantation
de valve aortique par voie percutanée (TAVI). Bien que ces choix aient un impact en termes de
consommation de ressources, aucune étude ne permet de le quantiﬁer et d’apporter une aide
à la décision dans le contexte européen.
Objectifs.— L’objectif était de fournir des données comparatives de coût de la procédure TAVI
du point de vue de l’hôpital en fonction de la voie d’abord et du type de salle utilisés ainsi que
de déterminer les facteurs associés au coût de séjour.
Méthodes.— Les données utilisées proviennent d’un registre national multicentrique correspon-
dant à 16 centres et à la période allant de janvier à octobre 2009. Une étude descriptive de
coût ainsi qu’une analyse multivariée du coût de séjour ont été effectuées sur une population
de 287 patients.
Résultats.— Les coûts moyens de la procédure TAVI et de l’hospitalisation initiale étaient res-
pectivement de 22 876D et 35 164D . Les coûts de la procédure ne différaient pas en fonction
de la voie d’abord et étaient les plus élevés en salle hybride et les moins élevés en salle de
cardiologie interventionnelle. Les facteurs associés à une augmentation de coût de séjour sont
la voie transapicale, un score STS supérieur à 10%, l’utilisation d’antivitamines K à l’inclusion,
la présence de complications lors de la procédure et la pose d’un pacemaker à la suite de
l’intervention.
Conclusion.— Si les conditions cliniques du patient le permettent, le personnel hospital-
ier pourrait être amené à trouver l’utilisation de la salle de cardiologie interventionnelle
économiquement plus avantageuse que celle de la salle hybride. Le coût moyen de
l’hospitalisation est supérieur au tarif remboursé en 2011. Cet écart s’est ampliﬁé depuis le
changement de règle tarifaire survenue en août 2012 représentant un frein au développement
de l’utilisation de TAVI en France.
© 2013 Publie´ par Elsevier Masson SAS.
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length of stay. Subgroup analysis distinguished patients byCosts in TAVI patients in France
Background
In 2002, the ﬁrst transcatheter aortic valve implantation
(TAVI) was performed in a patient with severe aortic stenosis
and cardiogenic shock, as a therapeutic alternative to car-
diac surgery for patients at high surgical risk. Since then,
over 50,000 patients are estimated to have been treated by
TAVI worldwide [1].
The safety and efﬁcacy of TAVI have been repeatedly
demonstrated [1—3] and 1-year as well as 2-year survival
rates were recently reported to be similar to those for
patients undergoing surgical valve replacement [4,5]. The
quality of life of patients has been shown to improve after
TAVI [6] and studies based on a randomized trial in the
USA using only the Edwards SAPIEN valve suggest that the
cost-effectiveness and cost-utility of TAVI are favourable
in inoperable patients [7,8]. However, no costing study
is available in the European context to provide informa-
tion on resource utilization and assist decision-making at
the national and hospital level, especially in countries
where payment is based on activity. Indeed, physicians
and hospital managers face the choice of several TAVI
devices, anatomical approach types (arterial or transapical)
and intervention sites (catheterization laboratory, operating
room or hybrid room) but lack comparative cost data in order
to make informed decisions when the choice is not clinically
driven.
The purpose of this study is therefore to provide these
comparative data for the cost of the TAVI procedure and the
hospital stay excluding the procedure cost, from a hospital
perspective, and to analyse factors associated with higher
cost.
Methods
Study design and population
Our study is based on the FRANCE registry, which has been
described in detail in previous publications [2]. In short, it
involved symptomatic adults requiring TAVI due to severe
degenerative valvular aortic stenosis and who were very-
high-risk patients for aortic valve replacement at the time of
enrolment. The registry is exhaustive because TAVI may only
be performed in France in authorized participating centres.
The FRANCE registry case report form (CRF) was designed
to collect detailed information on the resource require-
ments for the TAVI procedure and initial hospital stay, in
addition to the collection of clinical and quality of life data.
The subsequent FRANCE2 registry currently collects long-
term data on follow-up and adverse events [1]. The present
study presents the ﬁndings of the FRANCE registry, allow-
ing sound cost analysis; it reports on a total of 295 patients
included in 16 French centres between January and October
2009, of whom 287 patients underwent TAVI implantation
and were included. For the costing study, 11 patients were
excluded due to missing data (anatomical approach type,
device type, length of stay). For the analysis of hospital stay
cost predictors, 31 patients were excluded because death
occurred during the hospital stay and nine patients were
excluded due to missing data (anatomical approach type,
device type, length of stay).
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evices, procedure and intervention sites
atients received one of two models of prosthesis: the
dwards SAPIEN valve (Edwards Lifesciences, Irvine, CA,
SA) or the CoreValve (Medtronic, Minneapolis, MN, USA).
he Edwards SAPIEN valve (the SAPIEN XT valve was not
vailable at the time of the study) is a bioprosthetic valve
ade of bovine pericardial tissue mounted into a balloon-
xpandable stainless steel open-cell stent. The valve can
e implanted using the transfemoral (TF) or transapical
TA) approach, depending on the peripheral access. The
oreValve consists of a trileaﬂet bioprosthetic porcine peri-
ardial tissue valve mounted into a self-expandable nitinol
rame. It is generally implanted using the TF arterial
pproach or, less frequently at the time of data collection,
he subclavian approach (SC). There were no prespeciﬁed
ecommendations regarding the TF, SC or TA anatomi-
al approaches or for intervention sites used to implant
ither valve, which included the catheterization labora-
ory, the operating room and the hybrid room (a multiusage
ite equipped with both catheterization and anaesthesia
evices).
ata collection
fter informed consent, data were recorded using a stan-
ardized e-CRF and sent to a central database via the
nternet. Recorded data included demographic and clinical
atient data, data on the devices and other materials used
or the TAVI procedure, information about which anatomical
pproach and intervention site had been used, the duration
nd stafﬁng required for the procedure, the length of hos-
ital stay and the homogenous patient group code (groupe
omogène de malades; GHM), which is the accounting sys-
em code used for depicting the level of hospital resource
onsumption for a patient stay.
osting
hospital perspective was taken for costing. Unit costs have
een applied to the materials and stafﬁng resources used
n order to estimate the cost of the TAVI procedure, which
lso included overhead costs depending on the intervention
ite. As these costs are not available on a national basis,
aris hospital consortium average unit costs were used. The
ost of the hospital stay was estimated based on the cost
f the procedure and on direct and overhead cost items
elated to the patient’s GHM as identiﬁed in the national
ost scale for the medicine, surgery and obstetrics sector
ENC MCO, which features a detailed accounting system
hat evaluates the total cost of each hospital stay). As only
HM data for patients in hospitals with accounting systems
ere available (47% of the study population), we calcu-
ated the mean daily hospital costs excluding procedure cost
or these patients. To determine the cost of each hospital
tay, this daily amount was then multiplied by the patientrterial (TF and SC) or transapical (TA) approaches and
y intervention site. Costs are expressed in 2009 Euros
D ) and are displayed with and without the valve price
ncluded.
2F
s
O
W
a
r
w
p
s
v
P
h
V
c
d
c
d
c
o
c
s
a
m
r
A
l
w
[
S
B
a
e
u
e
u
t
s
u
b
s
c
e
m
c
S
R
d
c
S
A
o
v
d
u
c
T
(
t
t
a
S
(
R
P
D
p
p
s
t
p
c
t
a
P
T
T
f
b
a
t
r
i
a
s
a
S
T
s
1
f
m
r
T
t
w
w
l
m
laboratory (165± 58min) was signiﬁcantly lower than the
mean duration for patients treated in the operating room12
actors potentially associated with hospital
tay cost
utcome
hat was of interest was understanding the factors associ-
ted with higher hospital stay cost. As the cost of the valve
epresented a high ﬁxed-cost component (close to D 20,000
hich is over 62% of the tariff offer to hospitals for TAVI hos-
ital stays in 2011), it was not integrated and the outcome
tudied was the hospital stay cost on top of the cost of the
alve.
redictors: factors potentially associated with
igher hospital stay cost
ariables analysed include sociodemographic and clini-
al patient characteristics and treatment at inclusion, as
escribed previously [2]. Variables related to the pro-
edure included the type of anaesthesia (general/local),
evice type (Edwards/Medtronic), anatomical approach
hosen (arterial/TA), intervention site (catheterization lab-
ratory/operating room/hybrid room) and occurrence of
omplications during the procedure (yes/no). As clinical
cores assessing overall severity seemed likely to be over-
ll cost predictors, we constructed our analysis around two
ortality risk scores widely used in TAVI: the Society of Tho-
acic Surgeons (STS) score and the logistic Euroscore (LES).
n STS score > 10% and an LES > 20% are commonly used in the
iterature to deﬁne high-risk patients in valvular surgery so
e chose these values as thresholds for categorical analysis
9,10].
tatistical analyses
ecause of the skewed distribution of the cost, we used
gamma distribution with a log link in a generalized lin-
ar model. As the data have a hierarchical structure, the
nconditional means model was ﬁrst ﬁtted to test for centre
ffects, which were not detected.
Because classiﬁcations of patients in high-risk groups
sing the STS score and the LES are highly correlated,
wo different models were then tested with gamma regres-
ion: the STS score and all other variables except those
sed for its calculation; and the LES and all other varia-
les except those used for its calculation. Variables were
elected using the backward elimination method. Gamma
oefﬁcients generated by the regression models were
xponentiated to retransform them into rate ratio esti-
ates.
All statistical tests were two-sided. Statistical signiﬁ-
ance was accepted at P < 0.05. All data were analysed using
AS software version 9.3 (SAS Institute Inc., Cary, NC, USA).
esults are expressed as means± standard deviations while
ichotomous variables are presented as frequencies and per-
entages.
ensitivity analysisone-way sensitivity analysis was performed on the results
f the costing study to estimate the effect of potential
ariation in main variables. Hypotheses tested included a
(
P
f
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ecrease in the valve price that may follow an increase in
ptake of the TAVI, a decrease in the duration of the pro-
edure as a result of a learning effect after the diffusion of
AVI and, similarly, a decrease in the length of hospital stay
−10% and−20%, respectively). For the study of cost predic-
ors, the sensitivity analysis tested the effect of including
he patients who died during the hospital stay. A model was
lso performed that excluded the severity scores LES and
TS, replacing them with variables available in the e-CRF
described elsewhere [2]).
esults
opulation baseline characteristics
etailed baseline characteristics of the FRANCE registry
opulation have been described elsewhere [2]. In short,
atients undergoing TAVI by the TA approach did not differ
igniﬁcantly from those undergoing the arterial approach in
erms of age, sex, hypertension, diabetes, bypass surgery,
eripheral artery surgery, New York Heart Association class,
reatinine, warfarin treatment, LES, STS score and ejec-
ion fraction. However, they exhibited an aortic abdominal
neurysm more frequently (Table 1).
rocedural results
he arterial approach was performed more often than the
A approach (73% vs. 27%) and an Edwards valve was more
requently used than a CoreValve (66% vs. 34%). The com-
ination of an Edwards valve and the arterial approach
ccounted for 38% of patients. The catheterization labora-
ory was the most frequently used intervention site (67%),
egardless of the valve and approach type. The operat-
ng room was most frequently used to perform the TA
pproach, while the hybrid room was predominantly cho-
en to carry out TAVI using an Edwards valve by arterial
pproach.
tafﬁng and duration of the procedure
he TAVI procedure required, on average, 10 hospital
taff. The duration, with a mean of 182± 85min (median,
67min), decreased during the study period of 10months
rom a median of 177min to a median of 150min. The
ean duration did not differ signiﬁcantly when the arte-
ial approach was chosen (185± 87min) compared with the
A approach (175± 80min; P = 0.40). The mean duration of
he arterial procedure was signiﬁcantly longer for patients
ith an Edwards valve (193± 77min) compared with those
ith a CoreValve (174± 96min; P = 0.009), which was not
inked to a difference in the choice of intervention site. The
ean duration for patients treated in the catheterization229± 128min; P < 0.0001) or the hybrid room (220± 84min;
< 0.0001). The mean duration of the procedure did not dif-
er signiﬁcantly between the hybrid room and the operating
oom (P = 0.9206).
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Table 1 Patient characteristics at inclusion by approach chosen.
Approach Transapical (n = 78) Arterial (n = 209) P Total (n = 287)
Age (years) 82.18± 7.1 82.24± 7.12 0.959 82.22± 7.1
Female 29 (37.2) 103 (49.3) 0.067 132 (46)
Hypertension 58 (74.4) 146 (70.2) 0.488 204 (71.3)
Diabetes 23 (29.5) 60 (28.8) 0.915 83 (29)
Previous bypass surgery 24 (30.8) 50 (24) 0.247 74 (25.9)
Previous PAD surgery 9 (11.5) 13 (6.3) 0.135 22 (7.7)
Aortic abdominal aneurysm 8 (10.3) 8 (3.8) 0.045 16 (5.6)
NYHA III or more 60 (76.9) 155 (75.2) 0.768 215 (75.7)
Creatinine (mol/L) 139± 95 117± 53 0.145 123± 68
Warfarin treatment 26 (33.3) 59 (28.4) 0.413 85 (29.7)
Logistic Euroscorea > 20% 57 (76) 131 (66.2) 0.117 188 (68.9)
STS scoreb > 10% 37 (50) 101 (51.5) 0.822 138 (51.1)
Ejection fraction (%) 54± 12 53± 13 0.506 53± 13
Data are mean± standard deviation or number (%). NYHA: New York Heart Association; PAD: peripheral arterial disease; STS: Society of
Thoracic Surgeons. Note: percentages do not take into account missing values.
a The Logistic European System for Cardiac Operative Risk Evaluation (LES) score, which measures patient risk at the time of cardiovas-
cular surgery, is calculated by logistic regression; scores range from 0 to 100%, with higher scores indicating greater risk; an LES of > 20%
indicates very high surgical risk.
b The STS score measures risk at the time of cardiovascular surgery on a scale from 0 to 100%, with higher numbers indicating greater
risk; a score of > 10% indicates very high surgical risk.
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The average length of stay was 14.83± 11.04 days (median,
12 days) and decreased from a median of 13 days for the
ﬁrst third of patients (by order of implantation date) to a
median of 11 days for the last third. Mean length of stay did
not signiﬁcantly differ between the subgroups distinguishing
approach and intervention site.
Cost of the procedure
The total average cost of the TAVI procedure was D 22,876,
of which 85% was attributable to the valve price, 7% to other
material, 7% to stafﬁng and 1% to logistics (Table 2).
When the price of the valve was excluded, the average
procedure cost was D 3305. For patients treated in the cath-
eterization laboratory, the cost was signiﬁcantly lower than
in the other two settings (P < 0.001 for each) and it was sig-
niﬁcantly higher in the hybrid room than in the operating
room (P < 0.001). No signiﬁcant cost difference was observed
between the subgroups distinguishing approach type and
brand name of the valve. However, when the cost of the
valve was included, the cost of using Edwards for the arte-
rial approach was signiﬁcantly higher (+D 1160; P < 0.001)
(Table 3).
Cost of hospital stay
The total average cost of the initial hospital stay associated
with the TAVI procedure was D 35,164. When the price of
the valve was not included, the cost of the procedure was
21% of the average hospital stay cost, which amounted to
D 15,593 and was 44.3% of the total hospital cost. There
was no signiﬁcant cost difference between the subgroups
distinguishing approach type and intervention site (Table 4).
S
A
sactors associated with higher hospital stay
ost
or the robustness of the models, three patients with
xtreme length of stay (90, 87 and 65 days) were excluded.
e therefore performed the analysis on 244 patients.
Regardless of the variable included to assess severity (i.e.
n both the STS and the LES models), hospitals cost modelling
esults were quite similar. However, while an STS score > 10%
t inclusion was associated with increased hospital stay cost,
n LES > 20% was not signiﬁcant.
In both models, patients treated with warfarin at inclu-
ion, the TA approach, complications during procedure and
acemaker implantation during hospital stay following valve
mplantation were signiﬁcantly associated with higher hos-
ital stay cost. Receiving a pacemaker was associated with
36% increase in cost and this effect was approximately
ouble that of other factors associated with cost.
In the model assessing patient severity using the LES,
he use of the hybrid room was associated with increased
ospital stay cost (Table 5).
No signiﬁcant association with cost was found for the fol-
owing patient characteristics at inclusion: age, sex, use
f platelet inhibitors, New York Heart Association class,
jection fraction, severe aortic insufﬁciency, creatinine,
trial ﬁbrillation, left bundle branch block, previous cardiac
urgery, previous mitral replacement surgery, abdominal
ortic aneurism, peripheral arterial disease, smoking sta-
us, diabetes, hypertension, high cholesterol; nor for the
rocedural variables device type and type of anaesthesia.ensitivity analysis
s anticipated, one-way sensitivity analysis for the costing
tudy revealed a major impact of the valve price on the
214 K. Chevreul et al.
Table 2 Main unit costs (in D ) for transcatheter aortic valve implantation procedure and initial hospital stay.
Unit cost Mean cost per
patient± SD
Median cost
per patient
Procedure
Devices and consumablesa
Valveb 18,990 19,500 19,518
Catheter introducer 43.16 119 129
Wire guides 35.88 45 36
Diagnostic catheter 9.57 20 19
Temporary bipolar electrode 123.91 124 124
Valvuloplasty balloon 593.22 606 593
Inﬂation device 26.31 25 26
Percutaneous vascular suture system 557.86 536 558
Packed red blood cells or platelets 106.56 70 0
Other consumablesc 58 56
Total cost of devices and consumables 21,103± 2674 20,990
Staffd,e
Cardiac or vascular surgeon, interventional
cardiologist, anesthesiologist, radiologist
1.17 1022 916
Pump oxygenator nurse 0.83 40 0
Perioperative nurse 0.60 137 98
Anesthesiology nurse 0.62 98 93
Nurse 0.49 128 126
Nurse assistant 0.40 37 0
Radiology assistant 0.52 86 78
Total staff cost 1548± 786 1382
Intervention sited
Catheterization laboratory 0.99 160 149
Operating room 1.64 374 394
Hybrid room 0.99 352 394
Total room and ancillary cost 225± 150 174
Total cost of procedure 22,876± 2972 22,435
Hospital stay excluding procedure
Pacemaker 3186 521 0
Daily medical and overhead cost in addition
to procedure cost
801.3 11,767 9616
Total cost of hospital stay excluding procedure 12,288± 8917 9616
Total cost of hospital stay including procedure 35,164± 9450 32,577
SD: standard deviation.
a Source: Agency for Medicine Products and Devices, Paris Public Hospital System (AGESP, AP—HP).
b The unit costs of the Edwards SAPIEN valve and the Medtronic CoreValve (including the necessary placement kit) were D 19,517.50
and D 18,462.50, respectively.
c Other consumables included syringes, sutures, surgical staples, iodine and surgical protective covers.
d Cost is expressed per minute.
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he Source: working document provided by the ﬁnancial departmen
rocedure cost: a 20% reduction in the price would lead
o a 17% decrease in the procedure cost. Further, learn-
ng effects leading to a decrease in procedure time by 20%
ould reduce the procedure cost by almost 11%, excluding
he valve cost. The hospital stay cost excluding the valve
ost would decrease by 7% if the valve price was 20% lower
nd would decrease by 15% if the length of stay was 20%
horter (Fig. 1).
When the patients who died during the hospital stay
ere included in the multivariable analysis, all variables
igniﬁcantly associated with increased hospital stay cost in
D
T
mhe Paris Public Hospital System (AP—HP).
he initial analysis remained signiﬁcant. The model with-
ut severity scores but with their constituent variables
ound similar factors associated with higher cost (pacemaker
mplantation, warfarin use at inclusion, the TA approach, the
ybrid room and complications during the procedure).iscussion
his is the ﬁrst study to provide a comparative cost assess-
ent of the TAVI procedure and hospital cost and an analysis
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Table 3 Average cost of the transcatheter aortic valve implantation procedure (in D ), by type of anatomical approach and intervention site.
Approach Site Total
Transapical
(n = 76)
Arterial
(n = 200)
P Operating room
(n = 55)
Cath lab
(n = 189)
Hybrid room
(n = 32)
Pa
Valve included
Mean± SD 23,668± 4258 22,575± 2245 < 0.001 23,120± 3259 22,621± 2674 23,963± 3844 < 0.001 22,876± 2972
Standardized meanb 23,834 22,599 22,970 22,668 24,269 22,876
Median 22,810 22,279 22,443 22,298 23,509 22,435
Range [20,692;
45,275]
[19,164;
43,261]
[20,652;
45,275]
[19,164;
43,261]
[19,955;
44,073]
[19,164; 45,275]
Valve excluded
Mean± SD 3257± 959 3324± 915 0.552 3515± 1281 3124± 694 4016± 1016 < 0.001 3305± 926
Standardized meanb 3317 3375 3703 3130 4026 3305
Median 3131 3199 3490 3087 4258 3168
Range [1175; 6240] [702; 8906] [1175; 8906] [702; 5797] [1493; 5486] [702; 8906]
Cath lab: catheterization laboratory; SD: standard deviation.
a Intergroup.
b The standardized mean takes into account the distribution of intervention sites per approach type and the distribution of approach types per intervention site.
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Table 4 Average cost of the transcatheter aortic valve implantation hospital stay (in D ), by type of anatomical approach and intervention site.
Approach Site Total
Transapical
(n = 76)
Arterial (n = 199) P Operating room
(n = 55)
Cath lab (n = 188) Hybrid room
(n = 32)
Pa (n = 275)
Valve included
Mean± SD 36,362± 9972 34,706± 9228 0.205 35,312± 7779 34,594± 8802 38,257± 14,308 0.36 35,164± 9450
Standardized meanb 36,650 34,691 34,817 34,629 38,951 35,164
Median 32,671 32,386 32,712 32,149 33,305 32,577
Range [26,435; 74,874] [21,875; 94,061] [25,685; 59,773] [21,875; 94,061] [24,501; 93,487] [21,875; 94,061]
Valve excluded
Mean± SD 15,950± 8873 15,457± 8981 0.852 15,707± 7669 15,097± 8361 18,311± 13,146 0.415 15,593± 8938
Standardized meanb 16,133 15,468 15,550 15,092 18,707 15,593
Median 12,700 13,514 13,288 12,641 14,818 13,207
Range [6597; 55,356] [3093; 74,544] [7041; 40,256] [3093; 74,544] [3811; 73,970] [3093; 74,544]
Cath lab: catheterization laboratory; SD: standard deviation.
a Intergroup.
b The standardized mean takes into account the distribution of intervention sites per approach type and the distribution of approach types per intervention site.
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Table 5 Factors associated with hospital stay cost (valve excluded): results of the multivariable analysis.
Variable Model: STSa Model: LESb
Rate ratio (95% CI) P Rate ratio (95% CI) P
STS score at inclusion > 10% 1.15 (1.05—1.27) < 0.01 NA NA
LES at inclusion > 20% NA NA NR NR
Warfarin use at inclusion 1.15 (1.04—1.28) 0.01 1.16 (1.05—1.29) < 0.01
Transapical approach 1.14 (1.03—1.27) 0.02 1.14 (1.02—1.27) 0.02
Use of hybrid room NR NR 1.17 (1.02—1.36) 0.03
Complication(s) during procedure 1.19 (1.06—1.33) < 0.01 1.17 (1.05—1.29) < 0.01
Pacemaker implantation during
hospitalization
1.36 (1.20—1.54) < 0.001 1.36 (1.21—1.54) < 0.001
Adjusted R2 0.14 0.13
CI: conﬁdence interval; LES: Logistic Euroscore; NA: not applicable; NR: not retained in the ﬁnal model because not signiﬁcant; STS:
Society of Thoracic Surgeons.
a STS score and all other variables except those used for its calculation.
b LES and all other variables except those used for its calculation.
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Hospital stay cost excluding the procedure cost did not
iffer between patients undergoing TAVI by the arterial or
A approach or by intervention site used. However, the TA
pproach was associated with a higher hospital stay cost in
he modelling. This may be due to the fact that this approach
s used in a greater number of patients with worse health sta-
us. Indeed, clinical data show that patients undergoing the
A approach have higher mortality rates [1]. While limited
esearch evidence suggests that the steep learning curve
or the TA approach may be responsible for higher mortality
11], it is very likely that the risk proﬁle of these patients,
s reﬂected in a higher LES at inclusion, plays a determining
ole [2,12].
While it was not the case at the time of data collec-
ion, the arterial approach is now considered the ‘ﬁrst-line
reatment’, which means that patients undergoing the TA
pproach show contraindications for the arterial approach
2].
A similar explanation may be given concerning the hybrid
oom’s signiﬁcance in the model using the LES, while it is not
ssociated with higher cost in model using the STS score.
ndeed, among both severity score models, higher risk is
ssociated with higher cost only when using the STS score
nd not the LES.
Despite the fact that the LES was found to be linked to
ncreased 1-year mortality in the FRANCE2 registry [1], its
ack of statistical signiﬁcance is likely to be explained by
he way both scores were calculated. While both scores were
ot speciﬁcally designed and calibrated for TAVI patients but
or patients undergoing cardiac surgery in general [10], the
TS score takes operation-related factors into account much
ore precisely than the LES does, including factors speciﬁc
o valve surgery [13]. Moreover, evidence suggests that in
igh-risk patients with severe aortic stenosis, the STS score
s superior to the LES in predicting mortality [14].
The association of the hybrid room usage with higher cost
n the LES model should therefore be qualiﬁed by the fact
hat 90% of patients treated in a hybrid room have STS scores
igher than 10% versus only 59% among patients treated in
nother type of room. This leads us to believe that the hybrid
oom’s signiﬁcance was determined by the higher STS sever-
ty scores of the patients who were operated on in such
ooms.
Warfarin use at inclusion was also associated with higher
ospital stay cost in our study. We tested whether atrial
brillation as a frequent reason for warfarin use explained
his phenomenon but did not ﬁnd a signiﬁcant effect of atrial
brillation at inclusion in our multivariable model. Our ﬁnd-
ngs are, however, consistent with a study showing that in
atients with atrial ﬁbrillation, warfarin use was the main
redictor of hospital stay cost [15].
Finally, when compared with the speciﬁc TAVI DRG tar-
ff (code 1522) established by the statutory social health
nsurance in 2010 to pay hospitals for TAVIs, average total
ospital stay cost was higher taking into account supplemen-
al payments for intensive care (mean duration: 4.6 days)
nd pacemakers. With the growing use of TAVI, more recent
linical data (2010—2011) on the follow-up registry FRANCE2
uggest a nearly 10% decrease (D 31,863) in total hospital
tay cost and a 27% decrease (D 11,444) in hospital stay
ost excluding the valve cost. This is due to a decrease
n the mean length of stay (by 0.9 days) and in pacemaker
i
i
i
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mplantations (by 3.9%) and an increase in the share of
atients treated in the catheterization laboratory (by 7.7%)
2]. When using this estimate, total hospital stay cost was
hen very close to the applicable tariff (−1.6%) until changes
ere made in August 2012. Since then, the speciﬁc TAVI
RG tariff has been abolished and the valve price is now
aid on top of generic DRG tariffs for therapeutic pro-
edures with endovascular access except endoprosthesis
codes 1716, 1717, 1718, 1455). With an estimated average
ariff of D 8381, the hospital stay cost is more than D 3000
igher than the tariff paid. The average tariff excluding
alve was estimated by weighting each tariffs (codes 1716,
717, 1718, 1455), taking into account their frequency of use
rom August to November 2012 and by adding supplemental
ayment for intensive care and pacemaker.
tudy limitations
he FRANCE registry represents the ﬁrst experience with
AVI on French soil, limited to 16 hospital centres. Learning
urves are steep at the introduction of such innovations, as
mplied by the measured decrease in TAVI procedure dura-
ion and length of stay. Therefore, our evaluation may have
verestimated total cost, which is why alternative cost sce-
arios are provided in the sensitivity analysis.
With regard to data availability, stafﬁng, device and logis-
ic unit costs were based on Parisian hospital consortium
osts, which may not be similar in other settings (12 centres
ere outside of Paris). However, while wage mix can differ
cross hospitals, French public hospital wages are set at the
ational level and thus the average national wages presum-
bly are very close to the amounts we used. Moreover, device
excluding the valve) and logistic costs comprise 7% and 1%
f the total procedure cost, respectively, which means that
variation in the cost of these items is unlikely to have a
ajor effect on total procedure cost.
Further, the accounting system codes (GHM) were only
vailable for 47% of patients, which may have decreased
he accuracy of the hospital stay costing study. Never-
heless, the cost dispersion (mean, D 784; median D 754;
tandard deviation, D 201) and 95% conﬁdence interval
D 750—818) of the available GHMs were small, which leads
s to hypothesise that the missing data only had a minor
mpact.
Our hospital stay costing analysis used mean daily costs
eighted by length of stay, which is why hospital stay cost
s directly proportional to length of stay. As the marginal
ospital stay cost generally decreases during a hospital stay
16], our study is likely to overestimate the cost of long
tays and, vice versa, to underestimate the cost of short
tays. Also, the multivariable analysis of hospital stays is
quivalent to a model in which length of stay is used as
he outcome variable. Indeed, performing the multivariable
nalysis with length of stay as the outcome yielded similar
esults to those reported above (data not shown).
Finally, our multivariable analysis included variables that
ere chosen based on clinical assumptions and the availabil-ty of data. The adjusted R2 of 0.13 and 0.14, respectively,
ndicate that a main share of variation in hospital cost
s linked to variables that were not available for analy-
is.
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Conclusions
Based on the results of this study, assuming there are no clin-
ical reasons for choosing one option over another, hospital
staff may ﬁnd it economically favourable to opt for the use
of a catheterization laboratory as opposed to a hybrid room,
regardless of the approach chosen, However, when consid-
ering this choice within a broader perspective, one must
consider that in France, with the current tariff for TAVI hos-
pital stays below the cost incurred by the hospital, there is
an economic disincentive for the continued uptake of TAVI.
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